Confidence interval estimation for vaccine efficacy against COVID-19.
COVID-19
coverage probability
fixed number of events design
under-sensitivity
vaccine efficacy
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
01
2022
accepted:
22
07
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
This article focuses on the construction of a confidence interval for vaccine efficacy against contagious coronavirus disease-2019 (COVID-19) in a fixed number of events design. Five different approaches are presented, and their performance is investigated in terms of the two-sided coverage probability, non-coverage probability at the lower tail, and expected confidence interval width. Furthermore, the effect of under-sensitivity of diagnosis tests on vaccine efficacy estimation was evaluated. Except for the exact conditional method, the non-coverage probability of the remaining methods may exceed the nominal significance level, e.g., 5%, even for a large number of total confirmed COVID-19 cases. The narrower confidence interval width from the Bayesian, approximate Poisson, and mid-P methods are on the cost of increased instability of coverage probability. When the sensitivity of diagnosis test in the vaccine group is lower than that in the placebo group, the reported vaccine efficacy tends to be overly optimistic. The exact conditional method is preferable to other methods in COVID-19 vaccine efficacy trials when the total number of cases reaches 60; otherwise, mid-p method can be used to obtain a narrower interval width.
Identifiants
pubmed: 36033771
doi: 10.3389/fpubh.2022.848120
pmc: PMC9411791
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
848120Informations de copyright
Copyright © 2022 Wei, Wang and Yin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Stat Med. 1993 May 15;12(9):809-24
pubmed: 8327801
Lancet. 2021 Dec 11;398(10317):2173-2184
pubmed: 34774196
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Clin Trials. 2004;1(3):306-14
pubmed: 16279256
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Stat Methods Med Res. 2022 Feb;31(2):253-266
pubmed: 34931909
Epidemiol Rev. 1999;21(1):73-88
pubmed: 10520474
JAMA. 2021 Jul 6;326(1):35-45
pubmed: 34037666
Biometrics. 2001 Sep;57(3):963-71
pubmed: 11550951
Stat Med. 1996 Nov 15-30;15(21-22):2379-92
pubmed: 8931208
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Open Forum Infect Dis. 2020 Jul 24;7(8):ofaa315
pubmed: 32818146